JP2023536999A5 - - Google Patents
Info
- Publication number
- JP2023536999A5 JP2023536999A5 JP2023507966A JP2023507966A JP2023536999A5 JP 2023536999 A5 JP2023536999 A5 JP 2023536999A5 JP 2023507966 A JP2023507966 A JP 2023507966A JP 2023507966 A JP2023507966 A JP 2023507966A JP 2023536999 A5 JP2023536999 A5 JP 2023536999A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- pharmaceutical composition
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061384P | 2020-08-05 | 2020-08-05 | |
| US63/061,384 | 2020-08-05 | ||
| PCT/EP2021/071824 WO2022029209A1 (en) | 2020-08-05 | 2021-08-05 | Oligonucleotide treatment of hepatitis b patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023536999A JP2023536999A (ja) | 2023-08-30 |
| JP2023536999A5 true JP2023536999A5 (https=) | 2024-08-14 |
Family
ID=77595500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507966A Pending JP2023536999A (ja) | 2020-08-05 | 2021-08-05 | Ｂ型肝炎患者のオリゴヌクレオチド処置 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230357773A1 (https=) |
| EP (1) | EP4192955A1 (https=) |
| JP (1) | JP2023536999A (https=) |
| KR (1) | KR20230043877A (https=) |
| CN (1) | CN116194120A (https=) |
| AU (1) | AU2021322891A1 (https=) |
| CA (1) | CA3190794A1 (https=) |
| IL (1) | IL300340A (https=) |
| MX (1) | MX2023001443A (https=) |
| TW (1) | TW202221122A (https=) |
| WO (1) | WO2022029209A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA128786C2 (uk) | 2017-10-20 | 2024-10-23 | Дайсерна Фармасьютикалз, Інк | Олігонуклеотид для лікування інфекції гепатиту в |
| CN112534055A (zh) | 2018-07-13 | 2021-03-19 | 豪夫迈·罗氏有限公司 | 用于调节rtel1表达的寡核苷酸 |
| KR20240101580A9 (ko) * | 2021-11-11 | 2025-12-10 | 에프. 호프만-라 로슈 아게 | Hbv 치료를 위한 약학 조합물 |
| AU2024313135A1 (en) * | 2023-06-23 | 2026-01-22 | Brii Biosciences, Inc. | Assessment and treatment of chronic hepatitis b |
| WO2025006149A2 (en) * | 2023-06-27 | 2025-01-02 | HBVtech LLC | Methods for reducing hepatitis b virus surface antigen (hbsag) and the hepatitis b drugs used in the methods thereof |
| WO2025199466A1 (en) | 2024-03-22 | 2025-09-25 | Purdue Research Foundation | Liver-specific asialoglycoprotein receptor targeting ligands, conjugates comprising same, and related compositions and methods of use |
| KR20260008676A (ko) * | 2024-07-08 | 2026-01-16 | 항저우 티엔롱 파마슈티칼 컴퍼니 리미티드 | HBV 유전자 발현을 표적하고 조절하기 위한 이중 가닥 RNAi 제제 및 그 응용 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2336887T5 (es) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
| CA2429814C (en) | 2000-12-01 | 2014-02-18 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20050159378A1 (en) | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
| WO2003040395A2 (en) | 2001-11-07 | 2003-05-15 | Applera Corporation | Universal nucleotides for nucleic acid analysis |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| WO2007030167A1 (en) | 2005-09-02 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Modification of double-stranded ribonucleic acid molecules |
| DK2341943T3 (en) | 2008-09-22 | 2019-02-25 | Dicerna Pharmaceuticals Inc | COMPOSITIONS AND METHODS OF SPECIFIC INHIBITION OF DSRNA REPRINT WITH MODIFICATIONS |
| US8691971B2 (en) | 2008-09-23 | 2014-04-08 | Scott G. Petersen | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference |
| KR101728655B1 (ko) | 2008-12-18 | 2017-04-19 | 다이서나 파마수이티컬, 인크. | 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법 |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| WO2011005860A2 (en) | 2009-07-07 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | 5' phosphate mimics |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| EP2928877B1 (en) | 2012-12-06 | 2020-01-22 | Merck Sharp & Dohme Corp. | Disulfide masked prodrug compositions and methods |
| AU2015226206B2 (en) | 2014-03-07 | 2017-03-16 | F. Hoffmann-La Roche Ag | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection |
| CA2950960A1 (en) | 2014-06-06 | 2015-12-10 | Solstice Biologics, Ltd. | Polynucleotide constructs having bioreversible and non-bioreversible groups |
| SG11201704512PA (en) | 2014-12-08 | 2017-07-28 | Hoffmann La Roche | 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection |
| DK3569711T3 (da) | 2014-12-15 | 2021-02-22 | Dicerna Pharmaceuticals Inc | Ligandmodificerede dobbeltstrengede nukleinsyrer |
| CA2979490C (en) | 2015-03-16 | 2023-07-18 | F. Hoffmann-La Roche Ag | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
| RU2747822C2 (ru) * | 2016-03-14 | 2021-05-14 | Ф. Хоффманн-Ля Рош Аг | Олигонуклеотиды для понижения экспрессии pd-l1 |
| WO2017211791A1 (en) * | 2016-06-07 | 2017-12-14 | F. Hoffmann-La Roche Ag | Combination therapy of an hbsag inhibitor and a tlr7 agonist |
| HUE059718T2 (hu) | 2016-09-02 | 2022-12-28 | Dicerna Pharmaceuticals Inc | 4'-foszfát analógok és azokat tartalmazó oligonukleotidok |
| AU2018205995B2 (en) | 2017-01-06 | 2021-09-23 | F. Hoffmann-La Roche Ag | Solid forms of [(1S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-te trahydrofuran-2-yl]propyl] acetate |
| UA128786C2 (uk) * | 2017-10-20 | 2024-10-23 | Дайсерна Фармасьютикалз, Інк | Олігонуклеотид для лікування інфекції гепатиту в |
-
2021
- 2021-08-05 TW TW110128948A patent/TW202221122A/zh unknown
- 2021-08-05 MX MX2023001443A patent/MX2023001443A/es unknown
- 2021-08-05 CA CA3190794A patent/CA3190794A1/en active Pending
- 2021-08-05 KR KR1020237004356A patent/KR20230043877A/ko active Pending
- 2021-08-05 AU AU2021322891A patent/AU2021322891A1/en active Pending
- 2021-08-05 EP EP21763245.4A patent/EP4192955A1/en active Pending
- 2021-08-05 IL IL300340A patent/IL300340A/en unknown
- 2021-08-05 WO PCT/EP2021/071824 patent/WO2022029209A1/en not_active Ceased
- 2021-08-05 JP JP2023507966A patent/JP2023536999A/ja active Pending
- 2021-08-05 CN CN202180056772.5A patent/CN116194120A/zh active Pending
-
2023
- 2023-02-03 US US18/164,151 patent/US20230357773A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023536999A5 (https=) | ||
| US12486271B2 (en) | Solid forms of a toll-like receptor modulator | |
| JP7792371B2 (ja) | ＧａｌＮＡｃ誘導体 | |
| AU750026B2 (en) | Product comprising at least a double stranded RNA combined with at least an antiviral agent | |
| JP2022515778A5 (https=) | ||
| JP2018531272A6 (ja) | Ｈｂｖキャプシドアセンブリ阻害剤とインターフェロンの併用療法 | |
| WO2015181641A2 (en) | Combination of lenalidomide and polypeptide construct, and uses thereof | |
| JP2018531272A (ja) | Ｈｂｖキャプシドアセンブリ阻害剤とインターフェロンの併用療法 | |
| JP2015528449A5 (https=) | ||
| JP2013522302A5 (https=) | ||
| JP2005523946A5 (https=) | ||
| JP2018522540A5 (https=) | ||
| JP2023531520A5 (https=) | ||
| JP2018512428A5 (https=) | ||
| JP2009523010A5 (https=) | ||
| RU2010126598A (ru) | Применение человеческого антитела, способного нейтрализовать вирус гепатита в, для профилактики или лечения инфекции вирусом гепатита в | |
| CN115103674A (zh) | 使用tlr7激动剂治疗病毒感染的方法 | |
| JP2018533937A (ja) | Ｂ型肝炎表面抗原に対する抗体及びその使用 | |
| JP2024544532A5 (https=) | ||
| WO2021178612A1 (en) | Combination therapy for treating hepatitis b virus infection | |
| JP2025521124A (ja) | Ｂ型肝炎ウイルス（ｈｂｖ）感染及びｈｂｖ関連疾患を治療するための組成物及び方法 | |
| JP2023527918A5 (https=) | ||
| CN117083083A (zh) | Toll样受体7激动剂和抗PD-L1抗体的药物联合 | |
| Putra et al. | Immune Checkpoint Inhibitors (ICI) in the Functional Cure of Hepatitis B: A Narrative Review | |
| Guillevin | Synchronization of plasma exchange and adjuvant treatments |